Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print November 9, 2005, doi:10.1212/01.wnl.0000188667.66646.1c)
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
01.wnl.0000188667.66646.1cv1
66/1/127    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharma, M. K.
Right arrow Articles by Gutmann, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, M. K.
Right arrow Articles by Gutmann, D. H.
Related Collections
Right arrow Gene expression studies
Right arrow All Oncology
Right arrow Primary brain tumor
Right arrow Neurofibromatosis
NEUROLOGY 2006;66:127-130
© 2006 American Academy of Neurology
Brief Communications

Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma

M. K. Sharma, PhD, M. A. Watson, MD, PhD, M. Lyman, BS, A. Perry, MD, K. D. Aldape, MD, F. Deák, PhD and D. H. Gutmann, MD, PhD

From the Departments of Neurology (Drs. Sharma and Gutmann, M. Lyman) and Pathology and Immunology (Drs. Watson and Perry), Washington University School of Medicine, St. Louis, MO, Department of Pathology (Dr. Aldape), University of Texas M.D. Anderson Cancer Center, Houston, and Institute of Biochemistry (Dr. Deák), Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary.

Address correspondence and reprint requests to Dr Gutmann, Department of Neurology, Washington University School of Medicine, Box 8111, 660 S. Euclid Ave., St. Louis, MO 63110; e-mail: gutmannd{at}neuro.wustl.edu

Using whole genome expression microarray technology to discover clinically relevant biomarkers for pilocytic astrocytoma (PA), the authors identified matrilin-2 as a unique mRNA overexpressed in PA. Matrilin-2 protein expression was similarly elevated in the majority of sporadic PA, but in only one neurofibromatosis 1-associated PA with an unusually aggressive clinical phenotype. These results suggest that matrilin-2 may be a specific and clinically useful biomarker for discriminating between indolent and clinically aggressive PA.

This article was previously published in electronic format on November 9, 2005, as an Expedited E-Pub at www.neurology.org.

Supported by Schnuck Markets, Inc. (D.H.G.), and OM-255/02 (F.D.).

Disclosure: The authors report no conflicts of interest.

Received July 14, 2005. Accepted in final form September 23, 2005.




This article has been cited by other articles:


Home page
 NeurologyHome page
S. S. Houshmandi, E. I. Surace, H. B. Zhang, G. N. Fuller, and D. H. Gutmann
Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor
Neurology, November 28, 2006; 67(10): 1863 - 1866.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.